1. Validation of the Human Activity Profile Questionnaire in Patients after Allogeneic Hematopoietic Stem Cell Transplantation 
Philipp Yorck Herzberg, Pia Heussner, Friederike H.A. Mumm, Melanie Horak, Inken Hilgendorf, Stephanie von Harsdorf, Philipp Hemmati, Kathrin Rieger, Hildegard Greinix, Mathias Freund, Stephanie J. Lee, Ernst Holler, Daniel Wolff 
Biology of Blood and Marrow Transplantation 
Volume 16, Issue 12, Pages (December 2010)
DOI: /j.bbmt
Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
Influence of cGVHD severity according to the NIH Consensus (1 = mild, 2 = moderate, or 3 = severe) on the adjusted activity score (AAS).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
Influence of cGVHD severity according to the NIH Consensus (1 = mild, 2 = moderate, or 3 = severe) on the maximum activity score (MAS).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

4. Figure 3 Impact of change of cGVHD status on the MAS.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

5. Figure 4 Impact of change of cGVHD status on the AAS.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

6. Figure 5
Impact of change of cGVHD status on the physical functioning subscale of the SF36.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

7. Figure 6 Impact of change of cGVHD status on the FACT-BMT total score.
Figures 3-6. Mean MAS (Figure 3), AAS (Figure 4) of the HAP and Physical functioning subscale of the SF36 (Figure 5), and FACT-BMT total score (Figure 6) in correlation to the change of the overall severity of cGVHD (stable cGVHD [n = 52], improved cGVHD [n = 14], and progressive cGVHD [n = 8]) versus patients without cGVHD (n = 38). T1 refers to the time of inclusion, whereas T2 refers to evaluation 4-5 months after inclusion.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions